Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Update

Posted by Trina Covell on Mar 30th, 2025

Aspira Women’s Health Inc. (NASDAQ:AWH – Get Free Report) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 971,900 shares, a decrease of 35.6% from the February 28th total of 1,510,000 shares. Based on an average daily trading volume, of 4,090,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 7.7% of the shares of the stock are sold short.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its position in Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 33.8% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 316,294 shares of the company’s stock after buying an additional 79,898 shares during the period. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $256,000 as of its most recent filing with the SEC. 12.19% of the stock is currently owned by institutional investors and hedge funds.

Aspira Women’s Health Price Performance

Aspira Women’s Health stock opened at $0.11 on Friday. The firm has a market capitalization of $1.86 million, a P/E ratio of -0.09 and a beta of 1.57. The stock has a fifty day moving average price of $0.25 and a two-hundred day moving average price of $0.60. Aspira Women’s Health has a 52-week low of $0.08 and a 52-week high of $3.63.

Aspira Women’s Health (NASDAQ:AWH – Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.13. The firm had revenue of $2.35 million during the quarter, compared to the consensus estimate of $3.00 million.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Aspira Women’s Health in a research note on Sunday, January 12th. They set a “hold” rating for the company.

Get Our Latest Stock Analysis on Aspira Women’s Health

About Aspira Women’s Health

(Get Free Report)

Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.